Oncolytics Biotech Reports Strong Pelareorep Data in Pancreatic & Breast Cancers at AACR

summarizeSummary

This 8-K filing highlights significant positive clinical data for Oncolytics Biotech's lead immunotherapy candidate, pelareorep. The GOBLET study in metastatic pancreatic ductal adenocarcinoma demonstrated a 62% objective response rate, which the company states is more than double historical chemotherapy rates, alongside improved progression-free survival for patients with immune activation. This is a critical development given the high unmet medical need in pancreatic cancer. Additionally, data from the AWARE-1 study in early breast cancer showed pelareorep's ability to induce tertiary lymphoid structure formation, converting 'cold' tumors into 'hot' ones, suggesting broad applicability and potential synergy with other immunotherapies. The acceptance of these abstracts for presentation at the prestigious AACR Annual Meeting further validates the findings and provides a strong positive signal for the company's pipeline and future development.

check_boxKey Events

• Positive Pancreatic Cancer Data

  Pelareorep combination therapy achieved a 62% objective response rate in first-line metastatic pancreatic cancer, which the company states is more than double historical chemotherapy rates.

• Immune Activation in Pancreatic Cancer

  Biomarker data from the GOBLET trial showed patients with an immune activation signature experienced longer median progression-free survival (7.5 months vs. 5.6 months).

• Immune Conversion in Breast Cancer

  Data from the AWARE-1 study in early breast cancer demonstrated pelareorep's ability to drive coordinated anti-tumor immune responses, including tertiary lymphoid structure formation, potentially making immunologically 'cold' tumors more susceptible to immunotherapy.

• AACR Presentation Acceptance

  Two abstracts detailing these positive findings have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.

auto_awesomeAnalysis

This 8-K filing highlights significant positive clinical data for Oncolytics Biotech's lead immunotherapy candidate, pelareorep. The GOBLET study in metastatic pancreatic ductal adenocarcinoma demonstrated a 62% objective response rate, which the company states is more than double historical chemotherapy rates, alongside improved progression-free survival for patients with immune activation. This is a critical development given the high unmet medical need in pancreatic cancer. Additionally, data from the AWARE-1 study in early breast cancer showed pelareorep's ability to induce tertiary lymphoid structure formation, converting 'cold' tumors into 'hot' ones, suggesting broad applicability and potential synergy with other immunotherapies. The acceptance of these abstracts for presentation at the prestigious AACR Annual Meeting further validates the findings and provides a strong positive signal for the company's pipeline and future development.